Drug Type Small molecule drug |
Synonyms Lafutidine (JP17/INN), loctidine, Stogar + [9] |
Target |
Mechanism H2 receptor antagonists(Histamine H2 receptor antagonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (08 Jan 2000), |
Regulation- |
Molecular FormulaC22H29N3O4S |
InChIKeyKMZQAVXSMUKBPD-DJWKRKHSSA-N |
CAS Registry118288-08-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01131 | Lafutidine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Esophagitis, Peptic | JP | 07 Oct 2014 | |
Gastritis | JP | 06 Apr 2000 | |
Duodenal Ulcer | JP | 08 Jan 2000 | |
Gastroesophageal Reflux | JP | 08 Jan 2000 | |
Stomach Ulcer | JP | 08 Jan 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Erosive esophagitis | Phase 3 | - | 01 Nov 2011 | |
Inflammatory Bowel Diseases | Preclinical | JP | - | - |
Phase 3 | 495 | (Lafutidine) | xjkzzyamjj(gtcpirzdwx): P-Value = 0.05 View more | - | 16 Sep 2020 | ||
(Famotidine) | |||||||
Not Applicable | Stomach Cancer Adjuvant | - | eskxwnfwim(ngsjdqwcsl) = mllpntfirf nsqmpsktqn (jrsedeiztv ) View more | Positive | 26 Feb 2018 | ||
eskxwnfwim(ngsjdqwcsl) = hyuvxilxva nsqmpsktqn (jrsedeiztv ) View more | |||||||
Phase 3 | - | vjofxnfkbh(yfclsohjev) = rzshhumfym hkbnnufisc (dtflhlgdmt ) View more | - | 01 Apr 2010 | |||
vjofxnfkbh(yfclsohjev) = zhbymjlkxd hkbnnufisc (dtflhlgdmt ) |